miRTarBase - #MIRT443248


—
pre-miRNA Information
pre-miRNA hsa-mir-4763   
Genomic Coordinates chr22: 46113566 - 46113657
Description Homo sapiens miR-4763 stem-loop
Comment None
RNA Secondary Structure

Mature miRNA Information
Mature miRNA hsa-miR-4763-5p
Sequence 19| CGCCUGCCCAGCCCUCCUGCU |39
Evidence Experimental
Experiments Illumina
SNPs in miRNA
Mutant ID Mutant Position Mutant Source
rs374776264 1 dbSNP
rs1174502793 2 dbSNP
rs966122637 3 dbSNP
rs891363409 6 dbSNP
rs1303008773 8 dbSNP
rs1446379219 11 dbSNP
rs1410535134 13 dbSNP
rs1424733379 14 dbSNP
rs1372551711 16 dbSNP
rs756995936 17 dbSNP
Putative Targets

miRNA Expression profile
Human miRNA Tissue Atlas
Circulating MicroRNA Expression Profiling
Gene Information
Gene Symbol C9orf170   
Synonyms -
Description chromosome 9 open reading frame 170
Transcript NM_001001709   
Expression
Putative miRNA Targets on C9orf170
3'UTR of C9orf170
(miRNA target sites are highlighted)		 
>C9orf170|NM_001001709|3'UTR
   1 ATCTCTTTGGTAAATCCCCTGCCTAAATCCCCTGCCATGGAATAGCTGCCTAAACTTGGGCAAATAACTTGACATTTCTC
  81 AGTTTCCACATTCCAAAAATGGATTTTTATGAGAATTAAATGTTATGATGCATTCCAGCTACCTGTCCTAGAACCTGGCA
 161 TAAGAGCTCAGTACATGCTGGGGAGGGTTATCATCATCGTCATCATCATCTTATTAACATTCATGTTGAAGGGATGATGG
 241 GCTGCTGAGAAGTTCATGAAGAAGGTGAAAAACTATTACAGAGGTGGGAGGAAAAAGAGAGGACTATCACAGAAGCAGAA
 321 GAGCTGAGAGTATTGAGAAAGGGTGACGGGTTAGGGGGACTAGCAAGTACCCTCTGGCGTTGGCAATATTCAGTTTGTTG
 401 AAGGCCTTGATGAACTTTAATGAAGTGGTGAGAGTTAAACAAAGCTGAGATAGGATATGAATCTCAGGGAGGATATGAGG
 481 ACTCATTGATTACCATTCCAAGAAACTTGTCTGAAAAGGAAAGAAGAGATGGTGGTAATCAGAGCAGAGTGGCAGGATGC
 561 AGGGAGTTTTTATTTATTTATTTGTTCTTGTTGCTGACATTGTTTTCATACTATTTTTTGTTTGTTAAAGAGGGAGAGTT
 641 GTGAGTATAAAATAACCTATAAATAGGGAAAACCAGGAACAGATTCATGTGAAAGCCCTTGACTGAGAACAGAATTAATT
 721 ACCCGTGCAGAGGTAGTCTTCAAGCCTTGGCAGGTAAGCAACTGTCTGAGACACAGCTGGCTCGGGAACAGGGCCTTTCT
 801 TTGGCTGGCAGGCTTGAGGCAGCATAATTTGGAAGCGGATATGAGAAAGGGCATAATAATGTGAAATTTGACTGCCTAGT
 881 GGGGGAGAAACTTTGAATATTATGAGGCGGTTATGAAAGTATTTCCTTCTTATGGCTTCAATGGCACTGCCTCTGAGCAT
 961 TAGTGTTTGTCCTCAGGAGGTAAGTGTGGGGACTGTATCAGCAGTTACTACCTAGATAAGCACGGTGTATAGGGGTAACA
1041 TGGTTTATAGAGCATGCAAGCCTTCACCTCTTTGCTAGATGAGATATGGAACCTAAATTCGGAGACCACGTGACCCCTGA
1121 GGCATGGGGAGGTGGGGTCAGAAAGCGTTACTGGCCATGATCCAGACCCAGGCGTGGAGAAACGACCTACTGGGGTTTTC
1201 AGGGAGCAGGAAGGTGGGGCAGGTACAGAGTATATTCTGGGGGACAGTTTCATAAAAAGTGAGTAGATCTCCACAACTTA
1281 GTTTCTAGACTAAATGGACTAAGCATGTTCCGCCCTATTCTTCCTACTAACAATAACAAAAAGCTCTGGACAAAATTTAT
1361 AAAGCAACCCACAGAAGACTCCGAAGTTGGAAAAAGAAATAAAAACTGGCGATTTCCTCCATACTCAAGGCATCATGTAG
1441 CAGGGAGTGCCTTGGGTGTTGTTTATGTGTTTGTTTTCTTTTGTTCATTAATTTTTTTCTCCCGTGTATGGCAGTGTGGG
1521 CTCTAGCAATGCCTACCACCCGGAAACACAGATGGGTACAAATTTAAAAACCCCAAGAAAACTCTTTTTAGCCAAATGAC
1601 CAGTGTTTCCAGCAGAGCAAAAACATTTTGACCACATCTGCCCTTTTGTGCTGGCTAACCCCTTCCCCTGCCACCATGTG
1681 CTGCTGGGGGGACATTGTGGATGAAGCCCACTCATTTATTCCTCCTCCTGCAGTAATGTGACCATACCCTTCCCACTCCT
1761 AACTAGAGGCTGGGGGAGGACTATGTGGGGGAGAGAACTGGAGAAAGCAATTTTCTAAATTTGTGTATGAAATCCTGGTT
1841 AGAACTCTGAGTGCCCCATGCACAAAACAGACAAGAAACAACACAGCAAAAAGATTCAAGGGTCAGAAAAACTGAACACT
1921 GGTCTGAAACACTGCCCGGGTTTCAGATTGGCATCAGGGTAGCACCCAAGTGGGGCAGATTGAAATAGCACTGTAAAGGC
2001 TTTGAAAATGAAATGACTTTTGAGCCACAGCTCACAAAGTGAACCGGAACAAGCATTCTGAACTTAAACAGGTCAAGTGC
2081 CTGCTAAAATCAAAGACTGAAATGGGAACCAGAATAATATAACATACTACTGAAAATGTCTAGGATGCAATCCAAAATCT
2161 CATCACACTGAAAACCATAAAAATCTCAACTTGAAAGAGAAAAGGCAATTGTAAGCATTGAGATTACACAGATGTTGAAA
2241 CTATCCAGCAAGAATCATAAAGCAGCTATTATACAAATGCCCTGATTTTAAAGCAAGTATGAATGCTCGAAACAAATGAC
2321 AAAGTGGAAAGTCACAGCAGAGAAATAGAAAATGTAAGGAAGAACCAAATGGAAATTTTAAAACTGAAAAATACAATAAC
2401 CAGTTTTTAAAAATTACTAGATTCAGAGGGAAAGACCAACAACTCAGAAAAAATGGGCAAAGGATATGAAGAGTTTACGG
2481 AAAAGGAAATGTAGATAACTCTTACCCATATAAAAATATGTTCAGCCTCACTCATATAAGAAAAATCAAAATTGAAATTA
2561 CACTGAGACACTGCTTTTCACCTGTCAGAATGGCAAAACTCAAAGTGTGAATATACGCTATGAGAATGTGGAAAATTCTC
2641 ATAGATTGCTTGTGGGCATCTAGAACAATTTGGTTGAATCACTAAAATCCACATGCCATTTGGCCCTGCAATTCTACTTT
2721 TAGAAATTTATCATATAGGAAACCTGCATATGAGTGAAATGACATACGTGGAGTGTTACTCCTGGCTGCATTGTTGGTAA
2801 TCACAAAGAACACTAGAAAAAACTTAATGTCCATCAATAAGATGCTGATTAAATTAATTATTATACGTCATACAATGGAA
2881 AGTTAGAAAACCGTAAAAAAATGAAACCCTCTCTATAACCTGCTACCATATAATAAATAAAAGGACAGGCAATGAT
Target sites Provided by authors   Predicted by miRanda    DRVs    SNPs    DRVs & SNPs
miRNA-target interactions
(Predicted by miRanda)
ID Duplex structure Position Score MFE
1 
miRNA  3' ucGUCCUCCCGACCCGUCCGc 5'
            ||||| ||: |||||||: 
Target 5' agCAGGAAGGTGGGGCAGGTa 3'
 1205 - 1225 159.00 -28.80
2 
miRNA  3' ucguccucCCGACCCGUCCGc 5'
                  |||| ||||||| 
Target 5' ctttctttGGCT-GGCAGGCt 3'
 795 - 814 152.00 -17.50
3 
miRNA  3' ucguccUCCCGACCCGUCCGc 5'
                | | || ||||||: 
Target 5' gtcttcAAGCCTTGGCAGGTa 3'
 736 - 756 135.00 -11.10
Experimental Support 1 for Functional miRNA-Target Interaction
miRNA:Target ----
Validation Method
Conditions BC-3
Location of target site 3'UTR
Tools used in this research TargetScan , miRTarCLIP , Piranha
Original Description (Extracted from the article) ... PAR-CLIP data was present in GSM796039. RNA binding protein: AGO2. Condition:4-Thiouridine ...

- Gottwein E; Corcoran DL; Mukherjee N; et al., 2011, Cell host & microbe.

miRNA-target interactions (Provided by authors)
ID Duplex structure Position
1 
miRNA  3' ucguccucCCGACCCGUCCGc 5'
                  |||| ||||||| 
Target 5' ------uuGGCU-GGCAGGCu 3'
 		1 - 14
Article - Gottwein E; Corcoran DL; Mukherjee N; et al.
- Cell host & microbe, 2011
Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV) and frequently also harbors Epstein-Barr virus (EBV). The expression of KSHV- and EBV-encoded microRNAs (miRNAs) in PELs suggests a role for these miRNAs in latency and lymphomagenesis. Using PAR-CLIP, a technology which allows the direct and transcriptome-wide identification of miRNA targets, we delineate the target sites for all viral and cellular miRNAs expressed in PEL cell lines. The resulting data set revealed that KSHV miRNAs directly target more than 2000 cellular mRNAs, including many involved in pathways relevant to KSHV pathogenesis. Moreover, 58% of these mRNAs are also targeted by EBV miRNAs, via distinct binding sites. In addition to a known viral analog of cellular miR-155, we show that KSHV encodes a viral miRNA that mimics cellular miR-142-3p function. In summary, this study identifies an extensive list of KSHV miRNA targets, which are likely to influence viral replication and pathogenesis.
LinkOut: [PMID: 22100165]
CLIP-seq Support 1 for dataset GSM796039
Method / RBP PAR-CLIP / AGO2
Cell line / Condition BC-3 / 4-Thiouridine
Location of target site ENST00000375941.2 | 3UTR | UUGGCUGGCAGGCUU
Tools used in this analysis TargetScan, miRTarCLIP, and Piranha
Article / Accession Series PMID: 22100165 / GSE32109
CLIP-seq Viewer Link
MiRNA-Target Expression Profile
Dataset Pearson Correlation P-value for Pearson Correlation Spearman Correlation P-value for Spearman Correlation Samples Chart
MiRNA-Target Expression Profile (TCGA)
Tumor Pearson Correlation P-value for Pearson Correlation Spearman Correlation P-value for Spearman Correlation Samples Chart
69 hsa-miR-4763-5p Target Genes:
Functional analysis:
ID Target Description Validation methods
Strong evidence Less strong evidence
MIRT116035 DEPDC1 DEP domain containing 1 2 2
MIRT347197 SIN3B SIN3 transcription regulator family member B 2 2
MIRT443248 C9orf170 chromosome 9 open reading frame 170 2 2
MIRT475164 IP6K1 inositol hexakisphosphate kinase 1 2 2
MIRT495486 VTI1B vesicle transport through interaction with t-SNAREs 1B 2 2
MIRT496755 TGIF2 TGFB induced factor homeobox 2 2 2
MIRT496863 C21orf2 chromosome 21 open reading frame 2 2 2
MIRT499264 NBPF11 NBPF member 11 2 2
MIRT499517 MAFK MAF bZIP transcription factor K 2 2
MIRT512952 MKI67 marker of proliferation Ki-67 2 2
MIRT514656 NUP93 nucleoporin 93 2 2
MIRT517986 SLC16A13 solute carrier family 16 member 13 2 2
MIRT522816 KLHL9 kelch like family member 9 2 4
MIRT525495 CD63 CD63 molecule 2 2
MIRT528111 FOXH1 forkhead box H1 2 2
MIRT531683 MYO3A myosin IIIA 2 2
MIRT534806 RAB37 RAB37, member RAS oncogene family 2 2
MIRT573041 SHMT1 serine hydroxymethyltransferase 1 2 2
MIRT576720 Wars tryptophanyl-tRNA synthetase 2 2
MIRT609727 MLXIPL MLX interacting protein like 2 2
MIRT610843 FAM180B family with sequence similarity 180 member B 2 4
MIRT614735 STAT5A signal transducer and activator of transcription 5A 2 2
MIRT616981 EPOR erythropoietin receptor 2 2
MIRT617265 MMAB methylmalonic aciduria (cobalamin deficiency) cblB type 2 2
MIRT619405 INTS7 integrator complex subunit 7 2 2
MIRT621832 TIMM8A translocase of inner mitochondrial membrane 8A 2 2
MIRT621893 TAF13 TATA-box binding protein associated factor 13 2 2
MIRT630263 SMIM14 small integral membrane protein 14 2 2
MIRT634879 SENP8 SUMO/sentrin peptidase family member, NEDD8 specific 2 2
MIRT636863 ARSE arylsulfatase E (chondrodysplasia punctata 1) 2 2
MIRT637653 ADAT1 adenosine deaminase, tRNA specific 1 2 2
MIRT637699 ZNF439 zinc finger protein 439 2 2
MIRT637759 GATAD1 GATA zinc finger domain containing 1 2 2
MIRT638193 TAOK1 TAO kinase 1 2 2
MIRT638996 ADO 2-aminoethanethiol dioxygenase 2 2
MIRT642221 RABAC1 Rab acceptor 1 2 2
MIRT643327 ATCAY ATCAY, caytaxin 2 4
MIRT643419 ERVMER34-1 endogenous retrovirus group MER34 member 1, envelope 2 2
MIRT644499 RNF14 ring finger protein 14 2 2
MIRT644603 NT5DC3 5'-nucleotidase domain containing 3 2 2
MIRT644795 C21orf59 chromosome 21 open reading frame 59 2 2
MIRT648732 HIST1H2BD histone cluster 1 H2B family member d 2 2
MIRT653856 SHE Src homology 2 domain containing E 2 2
MIRT654129 RPL14 ribosomal protein L14 2 4
MIRT658876 DSN1 DSN1 homolog, MIS12 kinetochore complex component 2 2
MIRT671624 C20orf144 chromosome 20 open reading frame 144 2 4
MIRT677367 HSPA4L heat shock protein family A (Hsp70) member 4 like 2 2
MIRT677579 TRIM65 tripartite motif containing 65 2 2
MIRT678220 MACC1 MACC1, MET transcriptional regulator 2 2
MIRT679613 RRP36 ribosomal RNA processing 36 2 2
MIRT686081 PNPLA3 patatin like phospholipase domain containing 3 2 2
MIRT691817 ICA1L islet cell autoantigen 1 like 2 2
MIRT693869 COX19 COX19, cytochrome c oxidase assembly factor 2 2
MIRT694544 BPNT1 3'(2'), 5'-bisphosphate nucleotidase 1 2 2
MIRT694926 ANKS4B ankyrin repeat and sterile alpha motif domain containing 4B 2 2
MIRT697758 USP37 ubiquitin specific peptidase 37 2 2
MIRT697891 UBE2B ubiquitin conjugating enzyme E2 B 2 2
MIRT701569 MYPN myopalladin 2 2
MIRT703081 GPRIN3 GPRIN family member 3 2 2
MIRT708104 IGF2BP1 insulin like growth factor 2 mRNA binding protein 1 2 2
MIRT708320 NT5C 5', 3'-nucleotidase, cytosolic 2 2
MIRT709878 TRAF1 TNF receptor associated factor 1 2 2
MIRT713545 GJB1 gap junction protein beta 1 2 2
MIRT716275 NUP85 nucleoporin 85 2 2
MIRT716621 CRCP CGRP receptor component 2 2
MIRT717987 C9orf171 cilia and flagella associated protein 77 2 2
MIRT718438 RAB11B RAB11B, member RAS oncogene family 2 2
MIRT722544 AGPAT4 1-acylglycerol-3-phosphate O-acyltransferase 4 2 2
MIRT724013 F2RL1 F2R like trypsin receptor 1 2 2
miRNA-Drug Resistance Associations
miRNA Drug Name CID NSC FDA Effect/Pattern Detection Method Level Phenotype Condition
hsa-mir-4763 Cisplatin 5460033 NSC119875 approved sensitive High Gastric Cancer cell line (SGC7901)
hsa-mir-4763 Doxorubicin 31703 NSC123127 approved sensitive High Gastric Cancer cell line (SGC7901)
hsa-mir-4763 Fluorouracil 3385 NSC19893 approved sensitive High Gastric Cancer cell line (SGC7901)
hsa-mir-4763 Vincristine 5978 approved sensitive High Gastric Cancer cell line (SGC7901)
hsa-mir-4763 Dabrafenib 44462760 NSC764134 approved resistant cell line (A375)
hsa-mir-4763 Cisplatin 5460033 NSC119875 approved resistant cell line (BxPC3)
hsa-miR-4763-5p Anthracycline 30323 NSC82151 approved resistant High Breast Cancer tissue
hsa-miR-4763-5p Fluorouracil 3385 NSC19893 approved resistant High Breast Cancer tissue
hsa-miR-4763-5p Cyclophosphamide 2907 NSC26271 approved resistant High Breast Cancer tissue
hsa-miR-4763-5p Methotrexate 126941 NSC740 approved resistant High Breast Cancer tissue
hsa-miR-4763-5p Taxol 36314 NSC125973 approved resistant High Breast Cancer tissue
hsa-miR-4763-5p Temozolomide 5394 NSC362856 approved resistant cell line (U251)
hsa-miR-4763-5p Osimertinib 71496458 NSC779217 approved resistant cell line (PC9)
hsa-miR-4763-5p Tamoxifen 2733525 NSC180973 approved sensitive cell line (LCC2)
hsa-miR-4763-5p Platinum 23939 sensitive tissue (non-small cell lung cancer)
hsa-miR-4763-5p Neoadjuvant chemotherapy resistant tissue (breast cancer)
hsa-miR-4763-5p Neoadjuvant chemotherapy resistant tissue (breast cancer)
hsa-miR-4763-5p Gemcitabine 60750 NSC613327 approved resistant cell line (PANC-1) (1500 ng/ml)

Error report submission